Introduction

Name

• Clindamycin.
• Clindamycin hydrochloride.
• Clindamycin palmitate.
• Clindamycin phosphate.

Class of drug

• Lincosamide antibiotic.
• Bacteriostatic or bactericidal, depending on concentration.

Description

Chemical name

• (2S-trans)-methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-L-threo-alpha-D-galacto-octopyranoside.

Molecular formula

• C₁₈H₂₂C_lN₂O₅S.

Physical properties

• Multi-colored capsules.
• Round, white tablets, 25 mg and 75 mg are scored, 150 mg are not scored.
• Clear, colorless oral solution.
• Clear, colorless injection.

Storage requirements

• <25°C.
• Do not refrigerate.

Uses

Indications

• Anerobic and gram-positive infections including penicillin-resistant Staphylococci Staphylococcus spp.
• Mycoplasma Mycoplasma and ureaplasma, chlamydia, nocardia Nocardia spp.
• Many anerobes.
• Toxoplasmosis Toxoplasmosis , Neosporosis Neosporosis, Babesia Babesiosis, Pneumocystosis Pneumocystosis.
• More active than lincomycin Lincomycin.

Administration

Pharmacokinetics

Precautions

Interactions

with other drugs

Cross-resistance

• Complete cross-resistance between lincomycin Lincomycin and clindamycin.
• Partial cross-resistance with erythromycin Erythromycin.

Non-depolarizing muscle relaxants, eg tubocurarine

• May be increased by clindamycin.

Neostigmine and pyridostigmine

• See also neostigmine Neostigmine and pyridostigmine Pyridostigmine.
• May by antagonized by clindamycin.

Erythromycin

• See also erythromycin Erythromycin.
• Antagonize each other's effects in vitro; clinical significance unknown.

Ketoconazole

• See also ketoconazole Ketoconazole.
• May inhibit metabolism of clindamycin resulting in higher blood concentrations.

Adverse Reactions

Further Reading

Publications

Refereed papers

• Recent references from PubMed and VetMedResource.

Other sources of information

• BSAVA Small Animal Formulary. Ramsey I (2017) 9th edn.